<DOC>
	<DOCNO>NCT02904330</DOCNO>
	<brief_summary>This study first time K1-70 administer human . The principal aim study obtain safety tolerability data K1-70 administer IM injection subject Graves ' disease . Current therapy Graves ' disease include treatment anti-thyroid drug , destruction thyroid use radioiodine , total surgical thyroidectomy . Beta-blockers calcium antagonist may use control symptoms hyperthyroidism . K1-70 thyroid stimulate hormone receptor antagonist may provide new vivo diagnostic therapeutic tool management patient Graves ' disease , patient thyroid cancer patient would benefit control receptor activity .</brief_summary>
	<brief_title>K1-70 - A Study Subjects With Graves ' Disease</brief_title>
	<detailed_description>Graves ' disease one common overt autoimmune disorder . Patients Graves ' disease thyroid activity hyperthyroidism . Symptoms hyperthyroidism include goitre , fatigue , heat intolerance , sweat , weight loss despite good appetite , shakiness , inappropriate anxiety , palpitation heart , shortness breath , tetchiness agitation , poor sleep , thirst , nausea increase frequency defaecation . The rationale study obtain safety tolerability data K1-70 administer intramuscular injection subject Graves ' disease . This information , together pharmacokinetic data , help establish dos dosage regimen suitable repeat administration patient . This open-label study . The expected duration subject 's participation study approximately 18 week ( include screen period 4 week ) .</detailed_description>
	<mesh_term>Graves Disease</mesh_term>
	<criteria>Main age 1875 year Graves ' disease treat antithyroid medication OR treat antithyroid medication ( due sideeffects ) clinically biochemically euthyroid hyperthyroid body mass index ( weight [ kg ] /height [ ] 2 ) 18.5 35.0 kg/m2 Main current chronic history liver disease history cancer within last 5 year except localised skin cancer Graves ' orbitopathy clinical activity score &gt; 3/7 evidence optic neuropathy and/or corneal breakdown significant systemic infection history recurrent current infection splenectomy recently major surgery plan major surgery thromboembolic event due blood clot last 12 month clinically significant laboratory test clinically significant allergic condition ( exclude hay fever ) currently receive corticosteroid smoke 10 cigarette ( equivalent ) per day history drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>